Compare ANF & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANF | IRTC |
|---|---|---|
| Founded | 1892 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.7B |
| IPO Year | 1996 | 2016 |
| Metric | ANF | IRTC |
|---|---|---|
| Price | $98.85 | $112.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $120.50 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 915.1K | 501.3K |
| Earning Date | 05-27-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.71 |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $5,266,292,000.00 | $747,138,000.00 |
| Revenue This Year | $5.10 | $19.60 |
| Revenue Next Year | $3.83 | $15.94 |
| P/E Ratio | $63.82 | ★ N/A |
| Revenue Growth | 6.42 | ★ 26.24 |
| 52 Week Low | $65.45 | $100.85 |
| 52 Week High | $133.11 | $210.01 |
| Indicator | ANF | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 61.11 | 48.22 |
| Support Level | $98.80 | $111.37 |
| Resistance Level | $103.08 | $121.88 |
| Average True Range (ATR) | 4.14 | 4.94 |
| MACD | -0.01 | -0.90 |
| Stochastic Oscillator | 82.88 | 33.99 |
Abercrombie & Fitch Co is a digitally led, omnichannel retailer offering apparel, personal care products, and accessories for men, women, and kids through company-owned stores, digital channels, and third-party arrangements. The company operates through three geographic segments: Americas, the maximum revenue generator; Europe, the Middle East and Africa (EMEA); and Asia-Pacific (APAC). Its brand families include Abercrombie brands and Hollister brands. The Americas segment covers North and South America, EMEA includes Europe, the Middle East and Africa, and APAC includes the Asia-Pacific region, including Asia and Oceania.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.